Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Journal of Extracellular Vesicles|January 1, 2022
Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillanceElisabetta Vulpis, Luisa Loconte, Agnese Peri, et al.
Frontiers in Oncology|December 19, 2022
Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experienceFrancesco Autore, Luca Stirparo, Idanna Innocenti, et al.
Ejhaem|July 18, 2022
Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio groupFrancesca Fazio, Luca Franceschini, Valeria Tomarchio, et al.
Ejhaem|June 19, 2024
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in ItalyFrancesca Fazio, Maria Teresa Petrucci, Laura Corvatta, et al.
Leukemia & Lymphoma|September 2, 2020
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significanceSara Mohamed, Roberto Latagliata, Maria Zaira Limongi, et al.
Annals of Hematology|October 11, 2025
Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experienceAngela Rago, Francesca Fioritoni, Carmine Liberatore, et al.
Haematologica|October 6, 2022
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysisSilvia Mangiacavalli, Claudio Salvatore Cartia, Monica Galli, et al.
Pharmaceuticals (Basel, Switzerland)|April 26, 2025
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID StudyNicola Sgherza, Olga Battisti, Paola Curci, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2025
Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595Nicola Sgherza, Olga Battisti, Paola Curci, et al.
Haematologica|November 20, 2023
A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agentsRoberto Mina, Maria Teresa Petrucci, Francesca Bonello, et al.
Pageof 5